North America Is Dominating Clinical Trial Biorepository & Archiving Solutions Industry

In 2023, the global clinical trial biorepository & archiving solutions market generated revenue of USD 3,985.2 million, which is expected to grow at a compound annual growth rate of 8.2% to reach USD 6,916.6 million by 2030.

To learn more about this report: https://bit.ly/3RQt6TM

This growth of the market can be credited to the rising count of companies offering an extensive variety of services and the growing trend of outsourcing storage and other cold-chain processes so that the essential resources can concentrate more on medicinal development.

Furthermore, storage and transport techs are constantly advancing, which, combined with the l regulatory needs on bio-storage and the present trends in this space, can enormously help in saving money, time, and effort.

The clinical trial biorepository & archiving solutions industry is rising quickly because of the improvement in the obtainability of less expensive devices to compile data, for streamline reporting, using software that provides the functionality of a combined laboratory information management system made to aid in managing laboratory samples and information.

In 2023, the North American region dominated the clinical trial biorepository & archiving solutions market with the largest share of 55%, and the region is also estimated to continue with the dominance in the future. This is mainly because of the rising number of clinical trials, the presence of global market leaders, and the usage of progressive techs in the region. Furthermore, the presence of a huge count of service providers, CROs, and biopharmaceutical businesses enhances the market growth potential.

Hence, this growth of the market can be credited to the rising count of companies offering an extensive variety of services and the growing trend of the outsourcing of storage and other cold-chain processes, so that the essential resources can concentrate more on medicinal development.

Read More

Live Cell Imaging - Industry Growth and Future Analysis

The value of the live cell imaging market stood at USD 2,829.9 million in 2023, and this number is projected to reach USD 5,634.3 million by 2030, advancing at a CAGR of 10.4% during the projection period.

Live cell studies are an effective way of understanding the dynamics of cellular processes and events. For this reason, there has been an increasing adoption of live cell imaging technology in a wide range of fields such as drug discovery, healthcare research, stem cell biology, and cellular environment studies. 

Furthermore, the growing number of chronic diseases, in particular cancer, and the rapid adoption of high-content HHCS screening techniques for drug discovery are contributing to market growth.

Biotechnology and pharmaceutical businesses have accepted numerous progressive methodologies to overcome the challenges of saving time and money during medication safety and toxicity monitoring, one of which is HCS through cell-based assays. The technique is quicker and more precise and provides an advanced success rate than old-style approaches.

In 2023, the North American region led the worldwide industry, with a share of 50%. The supremacy of the continent can be credited to the growing occurrence of severe and chronic illnesses and the rising research and development spending of biotech and pharma businesses. During the projection period, the consumables category is projected to advance with a CAGR of 10.6%. 

The development is because of the increasing R&D in the biotechnology market, which generates a huge need for kits, reagents, and other consumables for lasting and fast live cell imaging and analysis.

Such reagents and consumables help in getting meaningful data, as they reserve cell health long sufficient for experts to extract whatever insights they require. Moreover, advanced reagents aid in generating rich data from a single cell, using fluorescent reagent blends in cell cultures. Thus, since consumables need to be obtained recurrently, the category will endure to advance.

Read More